Published in Virology on November 01, 1992
Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol (1999) 2.93
A viral function represses accumulation of transcripts from productive-cycle genes in mouse ganglia latently infected with herpes simplex virus. J Virol (1997) 2.83
Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol (1995) 2.66
A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO J (1998) 2.06
Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J Virol (1997) 1.86
Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo. J Virol (2002) 1.67
Herpes simplex virus type 1 immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. J Virol (1999) 1.66
Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol (1994) 1.51
Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential alpha27 gene. J Virol (1997) 1.45
PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant. J Virol (1994) 1.45
ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol J (2006) 1.41
Herpes simplex virus type 1 latency-associated transcripts suppress viral replication and reduce immediate-early gene mRNA levels in a neuronal cell line. J Virol (1998) 1.40
Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. J Virol (1995) 1.37
Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis. J Virol (2005) 1.27
Evidence that two latency-associated transcripts of herpes simplex virus type 1 are nonlinear. J Virol (1996) 1.23
The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection. J Virol (1993) 1.22
Analysis of the 2-kilobase latency-associated transcript expressed in PC12 cells productively infected with herpes simplex virus type 1: evidence for a stable, nonlinear structure. J Virol (1997) 1.21
Utilization of the herpes simplex virus type 1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system. J Virol (1997) 1.19
Viral replication is required for induction of ocular immunopathology by herpes simplex virus. J Virol (1996) 1.17
Analysis of a herpes simplex virus type 1 LAT mutant with a deletion between the putative promoter and the 5' end of the 2.0-kilobase transcript. J Virol (1994) 1.17
Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency. J Virol (1994) 1.15
Nuclear sites of herpes simplex virus type 1 DNA replication and transcription colocalize at early times postinfection and are largely distinct from RNA processing factors. J Virol (1997) 1.13
Herpes simplex virus type 1 latency-associated transcript (LAT) promoter deletion mutants can express a 2-kilobase transcript mapping to the LAT region. J Virol (1993) 1.11
Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. J Virol (2008) 1.06
The herpes simplex virus type 1 immediate-early protein ICP0 is necessary for the efficient establishment of latent infection. J Virol (1997) 1.06
Detection of herpes simplex virus type 1 latency-associated transcript expression in trigeminal ganglia by in situ reverse transcriptase PCR. J Virol (1996) 1.06
A recombinant herpes simplex virus type 1 expressing two additional copies of gK is more pathogenic than wild-type virus in two different strains of mice. J Virol (2007) 1.05
Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector. J Virol (1995) 1.05
Alternative splicing of the latency-related transcript of bovine herpesvirus 1 yields RNAs containing unique open reading frames. J Virol (1998) 1.03
Human corneal cells and other fibroblasts can stimulate the appearance of herpes simplex virus from quiescently infected PC12 cells. J Virol (1999) 0.94
Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression. J Virol (2000) 0.93
Herpes simplex virus type 1 2-kilobase latency-associated transcript intron associates with ribosomal proteins and splicing factors. J Virol (2001) 0.93
Role of dendritic cells in enhancement of herpes simplex virus type 1 latency and reactivation in vaccinated mice. Clin Vaccine Immunol (2008) 0.93
The transgenic ICP4 promoter is activated in Schwann cells in trigeminal ganglia of mice latently infected with herpes simplex virus type 1. J Virol (2001) 0.92
The herpes simplex virus type 1 latency-associated transcript promoter is activated through Ras and Raf by nerve growth factor and sodium butyrate in PC12 cells. J Virol (1996) 0.91
Genetic studies exposing the splicing events involved in herpes simplex virus type 1 latency-associated transcript production during lytic and latent infection. J Virol (1999) 0.86
Latent herpes simplex virus type 1 gene expression in ganglia innervating the human gastrointestinal tract. J Virol (1997) 0.86
cis-acting elements involved in transcriptional regulation of the herpes simplex virus type 1 latency-associated promoter 1 (LAP1) in vitro and in vivo. J Virol (1996) 0.83
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia (1999) 0.81
Genome wide nucleosome mapping for HSV-1 shows nucleosomes are deposited at preferred positions during lytic infection. PLoS One (2015) 0.78
Adaptive and innate transforming growth factor beta signaling impact herpes simplex virus 1 latency and reactivation. J Virol (2011) 0.78
A deletion at the UL/IR junction reduces pseudorabies virus neurovirulence. J Virol (1995) 0.75
RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. Proc Natl Acad Sci U S A (1987) 4.98
Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol (1993) 4.32
Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. EMBO J (1989) 3.65
In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model. J Virol (1991) 2.54
Latent herpes simplex virus type 1 transcripts in peripheral and central nervous system tissues of mice map to similar regions of the viral genome. J Virol (1988) 2.46
Is chronic hepatitis B being undertreated in the United States? J Viral Hepat (2010) 2.24
Latent herpes simplex virus type 1 transcription in human trigeminal ganglia. J Virol (1988) 2.02
Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia. Virology (1996) 1.96
A herpes simplex virus type 1 latency-associated transcript mutant reactivates with normal kinetics from latent infection. J Virol (1990) 1.83
In situ DNA PCR and RNA hybridization detection of herpes simplex virus sequences in trigeminal ganglia of latently infected mice. Virology (1995) 1.77
Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology (2001) 1.75
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A (1999) 1.54
Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A (1997) 1.46
Microinjection of pp60v-src into Xenopus oocytes increases phosphorylation of ribosomal protein S6 and accelerates the rate of progesterone-induced meiotic maturation. Mol Cell Biol (1984) 1.34
Phorbol ester, serum, and rous sarcoma virus transforming gene product induce similar phosphorylations of ribosomal protein S6. Proc Natl Acad Sci U S A (1984) 1.33
Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett (1998) 1.32
Novobiocin and coumermycin A1 inhibit viral replication and the reactivation of herpes simplex virus type 1 from the trigeminal ganglia of latently infected mice. J Virol (1987) 1.23
Evidence that two latency-associated transcripts of herpes simplex virus type 1 are nonlinear. J Virol (1996) 1.23
Investigation of herpes simplex virus type 1 (HSV-1) gene expression and DNA synthesis during the establishment of latent infection by an HSV-1 mutant, in1814, that does not replicate in mouse trigeminal ganglia. J Gen Virol (1991) 1.21
Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line. J Virol (1996) 1.20
Analysis of a herpes simplex virus type 1 LAT mutant with a deletion between the putative promoter and the 5' end of the 2.0-kilobase transcript. J Virol (1994) 1.17
The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol (1994) 1.15
Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency. J Virol (1994) 1.15
A herpes simplex virus type 1 mutant with a deletion immediately upstream of the LAT locus establishes latency and reactivates from latently infected mice with normal kinetics. J Neurovirol (1996) 1.13
Dissociation of the inhibitory effects of 2-deoxy-D-glucose on Vero cell growth and the replication of herpes simplex virus. Antimicrob Agents Chemother (1982) 1.04
Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc Natl Acad Sci U S A (1997) 1.03
A review of the molecular mechanism of HSV-1 latency. Curr Eye Res (1991) 1.03
Herpes simplex virus type 1 gene expression and reactivation of latent infection in the central nervous system. Neuropathol Appl Neurobiol (1994) 0.99
Inhibition of herpes simplex virus replication by methyl daunosamine. Antimicrob Agents Chemother (1982) 0.97
Atypical splicing of the latency-associated transcripts of herpes simplex type 1. Virology (1998) 0.96
Identification of a novel 0.7-kb polyadenylated transcript in the LAT promoter region of HSV-1 that is strain specific and may contribute to virulence. Virology (1999) 0.95
Human corneal cells and other fibroblasts can stimulate the appearance of herpes simplex virus from quiescently infected PC12 cells. J Virol (1999) 0.94
Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. J Virol (1999) 0.91
The HSV 1 genome in quiescently infected NGF differentiated PC12 cells can not be stimulated by HSV superinfection. J Neurovirol (2000) 0.87
Latency and reactivation of Marek's disease virus in B lymphocytes transformed by avian leukosis virus. J Gen Virol (1993) 0.86
Detection of HSV-1 proteins prior to the appearance of infectious virus in mouse trigeminal ganglia during reactivation of latent infection. Virus Res (1989) 0.85
Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processing in the endoplasmic reticulum. DNA Cell Biol (2001) 0.84
The UL55 and UL56 genes of herpes simplex virus type 1 are not required for viral replication, intraperitoneal virulence, or establishment of latency in mice. Virology (1994) 0.84
The HSV-1 latency associated transcript (LAT) variants 1704 and 1705 are glycoprotein C negative. Virus Res (1991) 0.84
The role of N-linked glycosylation in the secretion of hepatitis B virus. Adv Exp Med Biol (1998) 0.81
Effect of photoperiod on LH, FSH, prolactin and melatonin patterns in ovariectomized prepubertal heifers. J Reprod Fertil (1987) 0.80
Persistence of Marek's disease virus in a subpopulation of B cells that is transformed by avian leukosis virus, but not in normal bursal B cells. J Virol (1992) 0.80
Symptomatology and health attitudes of chronic hepatitis B patients in the USA. J Viral Hepat (2008) 0.80
Phosphorylation and protein synthetic events in Xenopus laevis oocytes microinjected with pp60v-src. Mol Cell Biol (1985) 0.78
A strategy for anti-viral intervention: the use of alpha-glucosidase inhibitors to prevent chaperone-mediated folding of viral envelope glycoproteins. Biochem Soc Trans (1997) 0.77
Sequences of herpes simplex virus type 1 that inhibit formation of stable TK+ transformants. J Virol (1987) 0.77
Characterization of mutants of herpes simplex viruses, types 1 and 2, that produce fragments of the thymidine kinase polypeptide. Can J Microbiol (1983) 0.77
Herpes simplex virus replication hits a nerve. J Neurovirol (1995) 0.75
The effect of photoperiod on diurnal rhythms of serum gonadotrophins, prolactin and melatonin in ovariectomized heifers. Domest Anim Endocrinol (1988) 0.75
herpes simplex virus infection accelerates the age-related reactivity of mouse trigeminal ganglia neurons with anti-mouse IgG antibody in immunostaining. Microb Pathog (1988) 0.75
Effects of lipofuscin on in situ hybridization in human neuronal tissue. J Virol Methods (1989) 0.75
Genetically engineered bacteria to identify and produce anti-viral agents. Adv Exp Med Biol (1992) 0.75